Atossa Therapeutics Q2 EPS $(0.05) Beats $(0.06) Estimate
Portfolio Pulse from Benzinga Newsdesk
Atossa Therapeutics (NASDAQ:ATOS) reported a Q2 EPS of $(0.05), beating the analyst estimate of $(0.06) and showing a 37.5% improvement from the $(0.08) loss per share in the same period last year.
August 12, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atossa Therapeutics reported a Q2 EPS of $(0.05), beating the analyst estimate of $(0.06) and showing a 37.5% improvement from the $(0.08) loss per share in the same period last year.
The better-than-expected EPS and significant year-over-year improvement are likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100